What Patients Need to Know About Lung Cancer Immunotherapy

Once thought of as a type of cancer that was unable to provoke an immune response, lung cancer has recently emerged as an exciting new target of immune-based therapies. The first immunotherapy approved by the FDA in the treatment of lung cancer in March 2015 and recent clinical trial developments are giving patients, like Maureen, new treatment options with impressive results.

On Friday, August 21, at 2:00 p.m. EDT, Julie Brahmer, MD, associate professor of oncology and interim director of the Johns Hopkins Sidney Kimmel Cancer Center, will discuss the latest research and current immunotherapies for patients with lung cancer.

Dr. Brahmer’s research and clinical practice focuses on the development of new therapies for the treatment and prevention of lung cancer and mesothelioma. She received her MD from the University of Nebraska Medical Center and her residency in internal medicine at The University of Utah. She completed her fellowship in oncology at the Johns Hopkins University School of Medicine and is also certified in medical oncology from the American Board of Internal Medicine. Dr. Brahmer is the Johns Hopkins principal investigator on the SU2C-ACS Lung Cancer “Dream Team” grant.

This 45-minute webinar, which is generously supported by Regeneron and a part of the Cancer Research Institute's Breakthrough in Cancer Immunotherapy webinar series, is free to the public, but seats are limited, so register now.

Register Today

Julie Brahmer, MD
Immunotherapy for Lung Cancer: What Patients Need to Know
Friday, August 21, 2015, at 2:00 p.m. EDT